If granted marketing authorization, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union (EU). Trofinetide is already approved in the United St We ...

Faced with the earlier setbacks with Nuplazid, the company has worked to add to its pipeline, and is hoping for FDA approval of its trofinetide candidate for neurological disorder Rett syndrome in ...

At the time of writing, one therapy has been approved for Rett syndrome, Acadia Pharmaceuticals’ $375,000-per-year Daybue (trofinetide), but Neurogene’s approach could offer a one-shot ...

Analyst Marc Goodman of Leerink Partners maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of ...

Diabetes and obesity are two metabolic diseases characterized by insulin resistance and a low-grade inflammation. Seeking an inflammatory factor causative of the onset of insulin resistance ...

After hours: February 3 at 4:23:24 PM EST Loading Chart for ACAD ...

After hours: January 31 at 6:12:24 p.m. EST ...